Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders
The past decades have yielded major therapeutic advances in many autoimmune conditions – such as multiple sclerosis (MS) – and thus ushered in a new era of more targeted and increasingly potent immunotherapies. Yet this growing arsenal of therapeutic immune interventions has also rendered therapy mu...
Main Authors: | Tobias Brummer, Tobias Ruck, Sven G. Meuth, Frauke Zipp, Stefan Bittner |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-08-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/17562864211035542 |
Similar Items
-
Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management
by: Stefan Bittner, et al.
Published: (2017-01-01) -
Comparative effectiveness of natalizumab ocrelizumab in multiple sclerosis: a real-world propensity score–matched study
by: Katrin Pape, et al.
Published: (2022-12-01) -
Spatial transcriptomics and neurofilament light chain reveal changes in lesion patterns in murine autoimmune neuroinflammation
by: Tobias Brummer, et al.
Published: (2023-11-01) -
Blood-brain barrier modeling: challenges and perspectives
by: Tobias Ruck, et al.
Published: (2015-01-01) -
NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study
by: Timo Uphaus, et al.
Published: (2021-10-01)